Literature DB >> 8813956

Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast.

G P Howes1, J Stephenson, S Humphreys.   

Abstract

AIMS/
BACKGROUND: Fine needle aspirates (FNAs) of breast lesions are now a routine investigation and prognostic information at this stage would be useful for accurate management, p53 gene status can be used as prognostic indicator, an abnormal genotype being associated with high grade, oestrogen receptor poor tumours. As the main disadvantage with FNA is poor cellularity, the objective of this study was to develop a sensitive and reliable method for the assessment of the p53 status of the lesion.
METHODS: Using PCR and subsequent direct sequencing, a method was developed that enables analysis of the p53 gene from relatively few malignant or suspicious cells in a background of normal cells.
RESULTS: This method is both reproducible and sensitive. The sensitivity of the method is demonstrated and a mutant cell can be seen in a background of 90% of normal wild type cells. A mutation, not previously described in breast cancer, is also reported in a symptomatic FNA.
CONCLUSIONS: This methodology is reliable and effective on samples with both variable cell numbers and quality of preservation, allowing it to be applied successfully to diagnostic cytology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813956      PMCID: PMC500572          DOI: 10.1136/jcp.49.7.570

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

2.  p53 protein overexpression and chemosensitivity in breast cancer.

Authors:  A Makris; T J Powles; M Dowsett; C Allred
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

3.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?

Authors:  D M Barnes; E A Dublin; C J Fisher; D A Levison; R R Millis
Journal:  Hum Pathol       Date:  1993-05       Impact factor: 3.466

4.  Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.

Authors:  S P Dowell; P O Wilson; N W Derias; D P Lane; P A Hall
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

6.  p53 mutation is associated with progression in follicular lymphomas.

Authors:  C A Sander; T Yano; H M Clark; C Harris; D L Longo; E S Jaffe; M Raffeld
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

7.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

Authors:  A M Davidoff; J D Iglehart; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.

Authors:  R D Petty; I A Cree; L A Sutherland; E M Hunter; D P Lane; P E Preece; P E Andreotti
Journal:  Biochem Biophys Res Commun       Date:  1994-02-28       Impact factor: 3.575

9.  Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.

Authors:  S S Sommer; J Cunningham; R M McGovern; S Saitoh; J J Schroeder; L E Wold; J S Kovach
Journal:  J Natl Cancer Inst       Date:  1992-02-19       Impact factor: 13.506

10.  p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.

Authors:  H Tsuda; K Iwaya; T Fukutomi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.